British Journal of Cancer - Table 1 for article: Combination chemotherapy in advanced gastrointestinal cancers: ex vivo sensitivity to gemcitabine and mitomycin C

FROM:

Combination chemotherapy in advanced gastrointestinal cancers: ex vivo sensitivity to gemcitabine and mitomycin C

P A Whitehouse, S J Mercer, L A Knight, F Di Nicolantonio, A O'Callaghan and I A Cree on behalf of the Portsmouth Upper GI and Colorectal Cancer Multidisciplinary Teams

BACK TO ARTICLE

Table 1. Summary of sensitivity data (using an arbitrary threshold of sensitivity defined as a IndexSUM<300 for six concentrations used)

Figure and tables index

Drug	No. assessed	No. sensitive	Sensitivity (%) (Index <300)	>95% Inhibition (%)
Oesophagogastric cancer
Mitomycin C	21	15	71	14 (three out of 21)
Gemcitabine	17	7	42	6 (one out of 17)
Mitomycin C+Gemcitabine	13	13	100	38 (five out of 13)

Colorectal cancer
Mitomycin C	39	21	54	10 (four out of 39)
Gemcitabine	38	19	50	3 (one out of 38)
Mitomycin C+gemcitabine	35	35	100	60 (21 out of 35)

Figure and tables index

BACK TO ARTICLE

TABLE 1

Combination chemotherapy in advanced gastrointestinal cancers: ex vivo sensitivity to gemcitabine and mitomycin C

Table 1. Summary of sensitivity data (using an arbitrary threshold of sensitivity defined as a IndexSUM<300 for six concentrations used)